Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Next-Generation Sequencing and the Diagnosis of Disease

In this interview, Professor John Rossen talks about next-generation sequencing and it's implications for the diagnosis of disease.

From Tecan 4 Aug 2021

New discovery could pave the way towards therapeutic treatments for many cancers

Princess Margaret Cancer Centre researchers have made new findings which provide a broader understanding of how dormant hematopoietic stem cells are activated and could pave the way towards therapeutic treatments for a number of cancers.

2 Aug 2021

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors.

29 Jul 2021

Removing RNA-binding protein in subtype of leukemia can help to slow the cancer's development

Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer's development and significantly increase the likelihood of survival, according to a study in mice led by scientists at the UCLA Jonsson Comprehensive Cancer Center.

28 Jul 2021

International collaboration aims to develop better therapy for childhood acute lymphoblastic leukemia

Scientists at St. Jude Children's Research Hospital are working with colleagues in China to develop better therapy for childhood acute lymphoblastic leukemia (ALL).

27 Jul 2021

Study may help refocus research efforts on adolescent and young adult cancer survivorship

Survival rates for adolescents and young adults diagnosed with cancer have varied considerably depending on cancer type.

26 Jul 2021

Comprehensive genomic sequencing essential to capitalize precision medicine for pediatric cancer care

St. Jude Children's Research Hospital investigators have demonstrated that comprehensive genomic sequencing of all pediatric cancer patients is feasible and essential to capitalize on the lifesaving potential of precision medicine.

26 Jul 2021

Chemotherapy drugs can induce mutations that lead to relapse in pediatric ALL patients

Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers.

22 Jul 2021

Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia

The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

21 Jul 2021

Protein markers in chronic lymphocytic leukemia may help determine patients' prognoses

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. New research published in the Journal of Leukocyte Biology reveals that certain protein markers may indicate which patients have stable forms of CLL and which have more aggressive types.

21 Jul 2021

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.

18 Jul 2021

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia.

16 Jul 2021

Dying patients with rare diseases struggle to get experimental therapies

At 15, Autumn Fuernisen is dying. She was diagnosed at age 11 with a rare degenerative brain disorder that has no known cure or way to slow it down: juvenile-onset Huntington's disease.

14 Jul 2021

Why we may never know whether the $56,000-a-year Alzheimer’s drug actually works

The Food and Drug Administration's approval in June of a drug purporting to slow the progression of Alzheimer's disease was widely celebrated, but it also touched off alarms.

12 Jul 2021

Metabolites of intestinal bacteria can positively influence the efficacy of tumor therapies

Certain metabolites of bacteria from the intestine make immune cells more aggressive as a new study conducted by scientists from Würzburg and Marburg reveals. The findings could help improve cancer therapies.

9 Jul 2021

Optical genome mapping could change the existing workflow within cytogenetic laboratories

Dutch-French research shows that Optical Genome Mapping (OGM) detects abnormalities in chromosomes and DNA very quickly, effectively and accurately. Sometimes even better than all existing techniques together, as they describe in two proof-of-concept studies published in the American Journal of Human Genetics.

8 Jul 2021

Researchers unravel mechanisms that produce individualized metabolism in leukemia

A research collaboration based in Kumamoto University (Japan) has shown that lysine-specific demethylase 1 (LSD1), an enzyme involved in gene expression, produces individualized metabolism depending on the type of acute myeloid leukemia cells.

6 Jul 2021

Research team identifies a way to improve immune response during viral infections

Melbourne researchers have identified a way to improve the immune response in the face of severe viral infections.

6 Jul 2021

A new study reveals unintended CRISPR/Cas9 editing events

A recent study by researchers from Sweden and the United Kingdom shows that CRISPR/Cas9-based genomic engineering can prompt unwanted on-target effects, and highlights the complexity of human DNA repair mechanisms in the presence of the powerful prokaryotic Cas9 nuclease. The paper is currently available on the bioRxiv* preprint server.

4 Jul 2021

Researchers reveal a promising target for designing anti-cancer therapies

Chances are, every one of us has been affected by cancer in one way or another. Unlike some other deadly diseases, cancer can take many forms inside the human body, so learning more about a single enzyme linked to many types of this disease could lead to more effective treatments.

2 Jul 2021